Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1

NCT02597803 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

317

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Syndrome

Interventions

DRUG: RGN-259
DRUG: Placebo

Sponsor

ReGenTree, LLC